Heart failure (HF) quality registries report quality of care but it is unknown whether they improve outcomes. The aims were to assess predictors of enrolment in a HF registry, test the hypothesis that enrolment in a HF registry is associated with reduced mortality, and assess potential explanatory factors for this reduction in mortality, if present. 
Introduction
Randomized clinical trials (RCTs) in heart failure (HF) have demonstrated improved morbidity and mortality from numerous medical and device therapies. These are outlined, summarized, graded, and updated in clinical practice guidelines 1 from cardiovascular (CV) societies. However, utilization of evidence-based interventions remains suboptimal 2 and, importantly, no specific interventions have convincingly been shown to improve utilization and, by extension, outcomes.
Numerous quality reporting and quality improvement registries have been developed and implemented in CV medicine, and may serve functions including quality reporting and improvement, benchmarking, patient empowerment, and standardization and promotion of equality of and access to care. In acute coronary syndromes, quality improvement registries demonstrated that within the registry, use vs. non-use of evidence-based interventions was associated with improved outcomes. 3, 4 Similarly, HF registries 2,5 -14 have characterized use of evidence-based interventions and some have observed that after joining these registries, hospitals have improved utilization of interventions and a favourable association between use of these interventions and outcomes. However, the selectivity of hospital participation and lack of suitable controls may limit the external validity of these findings. More importantly, these are all within-registry analyses, and it is unknown if observations extrapolate to non-enrolled patients. To our knowledge there have been no controlled or adjusted patient-level comparisons of registry-enrolled vs. not enrolled patients at a national level.
The Swedish Heart Failure Registry (SwedeHF) is a syndrome-specific nationwide voluntary quality reporting registry with 102 000 registrations in 62 559 patients between 2000 and 2014. The Swedish National Patient Registry (NPR) is a mandatory government-run administrative registration of ICD codes for all inpatient and specialist outpatient healthcare encounters. The Swedish universal standardized publicly funded healthcare system 15 together with these two and other data sources enable (i) assessment of factors associated with enrolment in the quality reporting registry; (ii) testing of the hypothesis that enrolment vs. non-enrolment is associated with reduced mortality; and (iii) assessment of potential explanatory factors for this potential reduction in mortality.
Methods

Patients
All permanent residents in Sweden have a unique 10-digit personal identification number enabling record linking between different quality and national health and census registries. Patients with new-onset HF registered in the Swedish NPR were included, and patients enrolled (exposure) vs. not enrolled (control) in the SwedeHF were compared.
The SwedeHF (http://www.SwedeHF.se) has been described previously. 2 clinics. Hospitalizations are registered as they occur and outpatient visits annually. The inclusion criterion is clinician-judged HF, regardless of ejection fraction (EF), thus including HF with both reduced (HFrEF), mid-range (HFmrEF) and preserved EF (HFpEF), with about 55% with EF <40%, 22% with EF 40-49%, and 23% with EF ≥50%. 16 Clinical characteristics and treatment are publicly reported in aggregate and by individual clinics (quality reporting), but there are at present no specific tools for decision-making (i.e. no specific quality improvement interventions). The protocol, case report form and annual reports are available at http://www.SwedeHF.se. Establishment of the SwedeHF was approved by a national ethics board. Patients do not provide written informed consent, but are informed of registration into national registries and allowed to opt out.
The NPR is a national mandatory registration of administrative records maintained by The Swedish Board of Health and Welfare (http://www.socialstyrelsen.se). The NPR has collected ICD diagnostic and procedure codes reported by clinicians in the medical record for hospitalizations since 1987 (ICD-9 1987-1997 and ICD-10 1998 to present), for outpatient visits in specialty (but not primary) care since 2001, and for patients undergoing outpatient surgical procedures 1997-2000. The positive predictive value for most diagnoses is 85-95%; 17 a HF diagnosis was verified in 86-91% of cases.
18
From all registrations in NPR, we included all consecutive patients with a first (incident) HF diagnosis, defined as ICD-10 code for HF in NPR (see the Supplementary material online, Table S1 ), between 2006 (when the Dispensed Drug Registry became available, see below) and 2013 (latest data available from NPR). We excluded repeated registrations in the same individual and patients with previous diagnosis of HF (prevalent HF) in the SwedeHF and/or NPR, age <18 years, and erroneous or invalid personal identification numbers or index or death dates ( Figure 1 ).
Independent baseline covariates
Baseline covariates (Table 1) were obtained as follows: index date by date of first registration in NPR; four demographic variables (age and gender by national identification number); inpatient vs. outpatient status provided by NPR; level of education provided by Statistics Sweden, the national census agency (http://www.scb.se); 17 relevant CV and non-CV co-morbidities provided by NPR (ICD-10 codes and definitions in the Supplementary material online, Table S2 ). There were no missing baseline data from the SwedeHF or NPR. Level of education was missing in a small proportion of patients and assigned its own category 'missing'. The HF-related clinical characteristics provided in the SwedeHF 2 are not available in NPR and were not used in this study.
Medication use
We compared the use of medication from the index date between the two groups. Eighteen relevant classes of medications were registered by the Dispensed Drug Registry (ATC codes in the Supplementary material online, Table S3 ). The 18 medications were categorized into six co-morbidity and 'frailty'-related medications (e.g. analgesics and anti-depressants), nine CV medications with no specific evidence for reducing mortality in HF (e.g. digoxin, statins, diuretics), and three HF-specific evidence-based medications [ Figure 1 Flow-chart of patient selection. HF, heart failure; SwedeHF, Swedish Heart Failure Registry.
all prescriptions dispensed by a pharmacy since 1 July 2005 (thus inclusion in this study from 2006). All pharmacies are required to participate by law and coverage is 100%. Swedish prescriptions are generally provided for 3-month intervals. Baseline use of medication after the index care episode was therefore defined as medication dispensed within 120 days after index date.
Enrolment in the SwedeHF, treatment, and outcome
We assessed the association between patient characteristics (21 variables) and treatment (18 treatments) and enrolment in the SwedeHF using several multivariable logistic regression models with a total of 39 variables as independent variables ( Figure 2 ) and enrolment in the SwedeHF as the dependent variable.
We assessed the association between enrolment in the SwedeHF and the outcome, all-cause mortality up to 16 April 2015, obtained from the Cause of Death Registry maintained by the Swedish Board of Health and Welfare as the dependent variable. For this, we used Kaplan-Meier survival analysis and several univariable and multivariable Cox regression models with adjustment for single or multiple baseline covariates (the same 39 variables as in the logistic regressions and year of enrolment). Person-time at risk was calculated from index date (incident HF) to the date of death or censoring at emigration or end of follow-up on 16 April 2015, whichever came first. There were no missing dependent or outcome data. Proportional hazards were confirmed by parallelism of Kaplan-Meier curves. survival curves in patients enrolled vs. not enrolled in the SwedeHF were shown for inpatients and outpatients separately. In addition, we repeated the multivariable logistic regressions assessing associations between patient characteristics and medication use and enrolment in the SwedeHF, and the multivariable Cox regressions assessing associations between enrolment and all-cause mortality, separately in inpatients and outpatients, and show these Forest plots in the Supplementary material online.
Subgroup analyses in inpatients and outpatients
Statistics was performed in SAS 9.4 (Cary, NC, USA). The level of significance was 5% and all P-values and confidence intervals were two-sided. This study received separate ethical approval beyond that existing for initial establishment of the SwedeHF. Data were acquired and analysed by L.H.L. and B.F.
Results
Patients
Between 1987 and 2013, there were 3 117 214 HF registrations in NPR, yielding 231 437 unique patients with incident HF diagnosed 2006-2013. Of these, 21 888 (9.5%; age 74 ± 13; 41% women; 68% inpatient) were enrolled in the SwedeHF, and 209 549 (90.5%; age 78 ± 12; 50% women; 79% inpatient) were not ( Figure 1 ).
Baseline characteristics
Patients in the SwedeHF were younger, more often male, with higher levels of education attained and less often registered as inpatients. They had similar prevalence of CV co-morbidities but fewer non-CV co-morbidities ( Table 1) . As all data are at time of first-time incident HF diagnosis, many characteristics differed from cohorts of prevalent HF, for example atrial fibrillation, which was present in 26% vs. 28%, which is much lower than the approximately 50% in prevalent HF in Sweden 16, 19 . Figure 2a shows adjusted odds ratios for the association between baseline characteristics and enrolment in the SwedeHF. Younger age, male sex and outpatient status were independently and strongly associated with increased odds of enrolment in the SwedeHF. Additional variables were modestly but significantly associated with enrolment, including higher education, pacemaker, and absence of numerous non-CV co-morbidities. Following the index event, patients in the SwedeHF had lower use of medications associated with comorbidity and frailty, such as analgesics and anti-depressants, and greater use of life-prolonging HF medications, oral anticoagulants and other CV medications such as digoxin and diuretics ( Table 1 ). These findings persisted after adjustment in multivariable logistic regression model. Most comorbidity and frailty-related medications, especially non-steroidal anti-inflammatory drugs (NSAIDs), were independently associated with non-enrolment in the SwedeHF (even independent of the co-morbidities themselves, which predispose to the use of these medications), whereas allopurinol was associated with enrolment ( Figure 2b) . In contrast, enrolment in the SwedeHF was associated with greater use of CV medications, especially RAS antagonists and beta blockers, which may be associated with improved outcomes, and diuretics, which may reflect greater severity of HF (Figure 2c) , and is consistent with greater use of allopurinol (Figure 2b) .
Association between baseline characteristics and medication use and enrolment in the SwedeHF
Association between enrolment in the SwedeHF and all-cause mortality
Median (interquartile range) follow-up until death or censoring alive was 874 (247-1667) days in the overall cohort. The number of deaths [95% confidence interval (CI)] per 100 patient-years of follow-up were 13.0 (12.7-13.3) vs. 20.8 (20.7-20.9) (P < 0.001). Figure 3 shows Kaplan-Meier survival curves for inpatients and outpatients in the SwedeHF yes vs. no. The curves diverge early with 1-year survival after incident HF diagnosis of 93.5% in enrolled outpatients, 88.2% in non-enrolled outpatients, 77.8% in enrolled inpatients, and 65.1% in non-enrolled inpatients (overall and pair-wise log-rank P-values all <0.001). Figure 4 shows hazard ratios for the association between enrolment in the SwedeHF and all-cause mortality throughout follow-up, unadjusted and adjusted for several single and combinations of baseline covariates. The unadjusted hazard ratio (HR) (95% CI) was 0.65 (0.63-0.66), P < 0.001. The HR moved closer toward 1.0 with sequential adjustment for baseline covariates: adjustment for five demographic variables 0.80 (0.78-0.81; P < 0.001); with an additional 17 co-morbidities the value was 0.82 (0.81-0.84; P < 0.001), and for an addition six co-morbidity medications the value was 0.82 (0.80-0.84; P < 0.001).
After further adjusting for nine CV medications and the interaction between atrial fibrillation/flutter and use of oral anticoagulants, the HR moved from 0. 
Results in inpatient and outpatient subgroups
The Supplementary material online shows Forest plots for inpatients and outpatients separately for adjusted log regression data for associations between clinical characteristics and medications with enrolment ( Figure S1 ) and Cox regression data for the association between enrolment and all-cause mortality ( Figure S2 ). There were no major differences.
Discussion
Quality reporting and improvement registries are accepted as integral parts of standardization and improvement of care, especially in the cardiovascular field. Within-registry analyses have identified gaps in care and associated use of evidence-based care with improved outcomes. Here we show, for the first time, that enrolment vs. non-enrolment in a HF quality registry is in itself associated with reduced mortality, and that this is explained by demographic differences and by better use of CV and evidence-based HF medications.
Selection bias for enrolment in a nationwide heart failure quality registry
While the SwedeHF is nationwide and includes 64 of 75 Swedish hospitals, coverage was only 9.5% of individual incident inpatient or outpatient HF encounters (although this may be somewhat underestimated because a few patients may be enrolled in the SwedeHF but not reported to NPR and thus excluded from the present study). Swedish nationwide guidelines recommend cardiology specialist care for HF patients, especially at first-time (incident) encounters (as in this study) and at times of treatment changes, but many patients may be seen instead in internal medicine or geriatrics departments. Cardiology departments or clinics in Sweden generally report to the SwedeHF, whereas internal medicine and geriatrics generally do not. Suboptimal reporting (9.5%) of new onset (incident) HF encounters to the SwedeHF may thus reflect initial contact with the healthcare system in internal medicine or geriatrics rather than in cardiology departments, and/or suboptimal reporting also in cardiology departments. Consistent with this, patients were indeed considerably more likely to be enrolled in the SwedeHF if they were younger and male, a pattern also seen, but more dramatically so, for clinical trials. 20, 21 The mean age of 78 years and 50% women among non-enrolled roughly reflects other epidemiological surveys 22 vs. 74 years and 41% women in the SwedeHF, which is comparable to other registries 5, 7 but still considerably different from HF trial populations [61 years and 11% women in angiotensin-converting 
Figure 4
Adjusted hazard ratios and 95% confidence intervals for all-cause mortality for enrolment in the Swedish Heart Failure Registry (SwedeHF) yes vs. no. The five demographic, 17 co-morbidity, and 18 medication variables are the same as shown in Figure 2 plus year of enrolment. CI, confidence interval; HF, heart failure. enzyme inhibitor trials 23 and 64-69 years and 19-25% women in beta blocker trials]. 24 While the level of education was higher for patients in the SwedeHF, only a minimal difference remained after covariate adjustment, suggesting that the difference reflected male sex and younger age rather than a selection bias on education level per se. Non-CV co-morbidities were somewhat less common in patients enrolled in the SwedeHF, even after adjusting for age, suggesting that co-morbid patients may receive less cardiology specialist care or less ambitious enrolment in the SwedeHF even if seen by cardiologists. In summary, these findings suggest that while the SwedeHF is considerably more generalizable than conventional clinical trial populations, there is still selection bias.
. Better quality of care in a heart failure quality registry associated with lower mortality
Some of the reduction in mortality in the SwedeHF (HR moving from 0.65-0.80; Figure 4 ) was explained by demographic selection bias. However, the remaining HR difference was explained by greater use of CV medications (HR moving only from 0.80 to 0.82 adjusting for co-morbidities and 'co-morbidity and frailty-related' medications but from 0.82 to 0.95 adjusting for nine CV medications and from 0.95 to 1.04 adjusting for RAS antagonists, beta blockers, and MRAs; Figure 4 ). Indeed, these HF agents were used in 82% vs. 56%, 84% vs. 60%, and 33% vs. 18%, in enrolled vs. non-enrolled, respectively, and in multivariable analyses, enrolment in the SwedeHF was strongly and independently associated with higher use of HF and CV medications, providing additional evidence for greater HF and CV medication use as an explanation for lower mortality in enrolled patients. In the present analysis, the aim was not to test whether these drugs are themselves individually associated with benefit, as this has previously been extensively documented in the SwedeHF, both for HFrEF and HFpEF. 16, 19, 25 -27 While there is no randomized evidence for these agents in HFpEF, at least half of patients in the SwedeHF have HFrEF. The proportion of MRA use was relatively low in both enrolled and non-enrolled patients, which may reflect concerns over complications, 28 and indeed MRAs have not been associated with improved outcomes in registry settings. 29 Use of cardiac resynchronization therapy and implantable cardioverter-defibrillators is not reported in the NPR and could therefore not be compared.
Limitations
Greater hospital volume is associated with better outcomes in HF, 30 which may confound analyses of voluntary registries; however, with 64 of 75 hospitals participating in the SwedeHF, this study is less subject to between-hospital variations. The SwedeHF collects information on numerous important HF characteristics that may affect both outcomes and treatment decisions, but as these are not available in NPR, they were not available for comparison or adjustment. Thus, there are numerous potential unmeasured confounders that may reflect within-hospital variation regarding selection for enrolment in the SwedeHF, as well as affect outcomes independent of enrolment in the SwedeHF. However, given the efficacy 23, 24 and effectiveness 16, 25 of HF medications and the fact that adjusting for CV and HF medications neutralized the benefit associated with enrolment in the SwedeHF, it is likely that the overwhelmingly greatest reason for enrolment in the SwedeHF was associated with reduced mortality due to greater use of these medications. We did not have access to doses or long-term use of medications, but our data suggest that initiation of any dose is adequate to explain a large part of the benefit associated with the SwedeHF. Sweden has many nurse-led HF clinics that are also more likely to enrol in the SwedeHF. In non-enrolled patients, we did not have information on participation in such clinics, but it is reasonable to assume that these clinics contribute to better use of HF and CV medications and thus better outcomes in enrolled patients. New-onset HF is diagnosed both in outpatients and inpatients, and we included both in the main analysis, with Kaplan-Meier survival assessed in inpatients and outpatients separately. Inpatient status was more common in non-enrolled patients but was adjusted for in multivariable models and subgroup analyses were provided. The outcome was all-cause mortality; CV deaths or events were not available. These findings are representative of Sweden but need to be validated in other healthcare systems.
Conclusions
Heart failure patients of male sex, younger age, and a higher level of education were more likely to be enrolled in a HF quality . registry. Enrolment was associated with reduced all-cause mortality that was largely explained by demographic differences and better utilization of CV and, in particular, HF medications.
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